Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445942 | 0.89 | BACE1 (0.48) | BACE1 | |
| SCHEMBL447809 | 0.80 | AKR1B1 (0.42) | BACE1LMNAPKMAKR1B1 | |
| SCHEMBL446378 | 0.75 | BACE1 (0.52) | BACE1 | |
| SCHEMBL448127 | 0.73 | BACE1 (0.37) | BACE1 | |
| SCHEMBL445432 | 0.72 | BACE1 (0.53) | BACE1 | |
| SCHEMBL449103 | 0.71 | AKR1B1 (0.50) | BACE1LMNAAKR1B1 | |
| SCHEMBL892392 | 0.69 | BACE1 (0.46) | BACE1AKR1B1 | |
| SCHEMBL892438 | 0.69 | BACE1 (0.43) | BACE1AKR1B1 | |
| SCHEMBL892011 | 0.69 | BACE1 (0.46) | BACE1AKR1B1 | |
| SCHEMBL892000 | 0.67 | BACE1 (0.62) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885LMNA 463/4885PKM 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.